Emerging MRD tests show promise in enhancing breast cancer treatment by improving risk stratification and clinical outcomes ...

VEN+O is a cost-effective treatment for untreated, fit CLL patients, offering superior progression-free survival and cost savings compared to most alternatives. The study used a cost-utility analysis, ...

Unfortunately, there are no currently available data or guidelines to support the safe de-escalation or cessation of ...

In an interview with Targeted Oncology ®, Stefania Morganti, MD, PhD, research fellow at the Dana-Farber Cancer Institute, ...

MRD detection via ctDNA poses challenges in managing breast cancer patients in complete remission, especially when imaging is ...

Panelists reflect on clinical experience with immunotherapy combinations, the role of biomarkers, and the future of ...

The FDA has approved durvalumab (Imfinzi) plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for the treatment ...

Recent polling shows oncologists changing inclination in treatment for mHSPC based on tolerability profiles.

Benjamin George, MD, has significantly improved cancer care access in rural Nebraska, Colorado, and Kansas, transforming ...

Comprehensive biomarker testing is central to the management of metastatic non-small cell lung cancer (NSCLC). Widespread ...

Circulating tumor DNA (ctDNA) revolutionizes minimal residual disease detection, offering a less invasive, real-time method ...

The IGNYTE trial reveals that RP1 combined with nivolumab offers significant, durable responses in advanced melanoma patients ...